Allogeneic Cell Therapy Market by Type, Application, End-Use

Description

List of Tables

[187 Pages Report] The Allogeneic Cell Therapy Market size was estimated at USD 2.04 billion in 2023 and expected to reach USD 2.31 billion in 2024, at a CAGR 13.90% to reach USD 5.08 billion by 2030.

Allogeneic cell therapy involves medical treatments wherein cells are transferred from a single healthy donor to multiple patients to help treat various diseases, including certain cancers, autoimmune diseases, and heart conditions. Ongoing advances in genetic engineering, cell processing, and culturing techniques have significantly enhanced the efficacy and safety of allogeneic cell therapies, fueling market growth. The growing incidence of cancers, autoimmune diseases, and cardiovascular conditions globally drives the demand for innovative treatments such as allogeneic cell therapy. Favorable government policies worldwide and increased funding for research in cell-based therapies have accelerated market expansion. However, high costs associated with the development and administration of allogeneic cell therapies limit accessibility for a broader patient base. Immune rejection and the need for immunosuppressants to avoid adverse reactions remain significant challenges for market growth. Moreover, continuous research aiming at improving cell sourcing, preservation, and scalability presents substantial opportunities for market growth. Developing tailored allogeneic cell therapy solutions catering to individual patient profiles may open new avenues for personalized medicine.

KEY MARKET STATISTICS
Base Year [2023]	USD 2.04 billion
Estimated Year [2024]	USD 2.31 billion
Forecast Year [2030]	USD 5.08 billion
CAGR (%)	13.90%

Type: Growing adoption of mesenchymal stem cell therapy due to anti-inflammatory and immunomodulatory properties

Chimeric antigen receptor T cell therapy (CAR-T) involves the introduction of a chimeric antigen receptor that specifically targets cancer cells, providing a personalized approach to cancer therapy. CAR-T cell therapy is primarily employed for certain types of blood cancers including non-Hodgkin lymphoma and acute lymphoblastic leukemia for improved outcomes. Hematopoietic stem cell transplantation is responsible for the transplantation of stem cells from a donor (allogeneic) to replace damaged bone marrow with healthy stem cells. Hematopoietic stem cell transplantation is the treatment of choice for patients with certain leukemias, lymphomas, and genetic blood disorders when other treatments are not effective or as a part of the treatment plan. Induced pluripotent stem cell therapy (iPSC) is derived from skin or blood cells reprogrammed back into an embryonic-like pluripotent state. iPSC technology is primarily utilized for regenerative medicine, disease modeling, and drug discovery. Mesenchymal stem cell therapy has the ability to differentiate into various cell types and possesses anti-inflammatory and immunomodulatory properties.

Application: Revolutionizing allogeneic cell therapy's role in treating and improving organ transplantation procedures

Allogeneic cell therapy has significantly improved the treatment of hematological disorders, such as leukemia and lymphoma. In oncology therapies, allogeneic cell therapy is utilized to fight against various cancer forms, leveraging the immune system's capacity to attack cancer cells.

Regenerative medicine represents the most exciting areas of allogeneic cell therapy, focusing on repairing, replacing, and regenerating human cells, organs, or tissues to restore normal function. Allogeneic cell therapy also plays a pivotal role in solid organ transplantation, particularly in reducing the risk of transplant rejection and the need for lifelong immunosuppression.

Regional Insights

The Americas, particularly the United States and Canada, are at the forefront of the allogeneic cell therapy industry, driven by robust investments, cutting-edge research, and a supportive regulatory environment that is increasingly conducive to innovation in biotechnology. Intellectual property developments, typified by a steady stream of patents related to cell processing techniques and bioreactor designs, demonstrate the vibrancy of the market in the Americas region. The European Union observes strong government and private support for regenerative medicine, including allogeneic cell therapy. Countries such as Germany, the United Kingdom, and France have been particularly active, with numerous clinical trials and research initiatives, and also benefit from a regulatory framework encouraging innovation while ensuring patient safety. Middle East countries such as the United Arab Emirates and Saudi Arabia, are investing significantly in healthcare infrastructure and have shown interest in adopting advanced medical treatments, including cell therapies. The African region is more diverse, with South Africa leading in terms of research and interest in regenerative medicine. In the APAC region, China has made remarkable strides, with substantial government backing for biotechnology research. Japan and India have a well-established reputation for pioneering regenerative medicine, supported by favorable regulatory policies to fast-track promising therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Allogeneic Cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Allogeneic Cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Allogeneic Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., AlloSource, Anterogen.Co., Ltd., Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies, Athersys Inc., Biorestorative Therapies Inc., Biosolution Co., Ltd., Bloodworks Northwest, Brainstorm Cell Limited, Caribou Biosciences, Fate Therapeutics, Gamida Cell, Hope Biosciences, JCR Pharmaceuticals Co., Ltd., Mallinckrodt Pharmaceuticals, MEDIPOST Co., Ltd., Mesoblast Ltd., NuVasive Inc. by Globus Medical, RTI Surgical, Smith+Nephew PLC, Stempeutics Research Pvt. Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Tego Science Inc., and ViaCyte Inc. by Vertex Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Allogeneic Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Chimeric Antigen Receptor T Cell Therapy
- Hematopoietic Stem Cell Transplantation
- Induced Pluripotent Stem Cell Therapy
- Mesenchymal Stem Cell Therapy

Application
- Hematological Disorders
- Oncology
- Regenerative Medicine
- Solid Organ Transplantation

End-Use
- Biotechnology & Pharmaceutical Companies
- Hospitals & Clinics
- Research Institutes

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Allogeneic Cell Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Allogeneic Cell Therapy Market?

3. What are the technology trends and regulatory frameworks in the Allogeneic Cell Therapy Market?

4. What is the market share of the leading vendors in the Allogeneic Cell Therapy Market?

5. Which modes and strategic moves are suitable for entering the Allogeneic Cell Therapy Market?

Product Code: MRR-CA100284D019

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing incidences of cancers, autoimmune diseases, and cardiovascular conditions
  - 5.1.1.2. Favorable government policies and increased funding for research in cell-based therapies
- 5.1.2. Restraints
  - 5.1.2.1. Complex regulatory environment for development and administration of allogeneic cell therapies
- 5.1.3. Opportunities
  - 5.1.3.1. Development of personalized allogeneic cell therapy solutions
  - 5.1.3.2. Exploration into the new treatment avenues in neurodegenerative diseases and cardiac diseases
- 5.1.4. Challenges
  - 5.1.4.1. Immune rejection and compatibility issues
5.2. Market Segmentation Analysis
- 5.2.1. Type: Growing adoption of mesenchymal stem cell therapy due to anti-inflammatory and immunomodulatory properties
- 5.2.2. Application: Revolutionizing allogeneic cell therapy's role in treating and improving organ transplantation procedures
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Allogeneic Cell Therapy Market, by Type

6.1. Introduction
6.2. Chimeric Antigen Receptor T Cell Therapy
6.3. Hematopoietic Stem Cell Transplantation
6.4. Induced Pluripotent Stem Cell Therapy
6.5. Mesenchymal Stem Cell Therapy

7. Allogeneic Cell Therapy Market, by Application

7.1. Introduction
7.2. Hematological Disorders
7.3. Oncology
7.4. Regenerative Medicine
7.5. Solid Organ Transplantation

8. Allogeneic Cell Therapy Market, by End-Use

8.1. Introduction
8.2. Biotechnology & Pharmaceutical Companies
8.3. Hospitals & Clinics
8.4. Research Institutes

9. Americas Allogeneic Cell Therapy Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Allogeneic Cell Therapy Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Allogeneic Cell Therapy Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Getinge's Strategic Partnership with CellRev to Revolutionize Allogeneic Cell Therapy Manufacturing
- 12.3.2. StemCyte's Pioneering Agreement for Advancing Worldwide Access to Groundbreaking Cord Blood-Derived Cell Therapies
- 12.3.3. FDA Approval of Gamida Cell's Omisirge Therapy as Transformative Leap in Hematological Cancer Treatment
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio